For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Mirati Therapeutics, Inc.

USPTO Granted Patents = 44

EPO Patents = 12

Trademarks = 19

Forward Citations = 104

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

Matthew Arnold Marx (30 out of 30 patents)

James Gail Christensen (23 out of 24 patents)

Aaron Craig Burns (16 out of 20 patents)

4. John Michael Ketcham (16 out of 24 patents)

5. Christopher Ronald Smith (14 out of 29 patents)

6. John David Lawson (13 out of 27 patents)

7. John Peter Fischer (12 out of 30 patents)

8. Jay Bradford Fell (11 out of 27 patents)

9. Tony P Tang (11 out of 44 patents)

10. Xiaolun Wang (11 out of 26 patents)

11. Macedonio J Mejia (10 out of 14 patents)

12. Mark Joseph Chicarelli (10 out of 47 patents)

13. Pavel Savechenkov (10 out of 10 patents)

14. James F Blake (8 out of 113 patents)

15. Thomas P Bobinski (8 out of 10 patents)

Core Competencies:

KRas G12D Inhibitors

Adagrasib

PRC2 Inhibitors

Combination Therapies

Pan-KRas Inhibitors

LSD1 Inhibitors

EZH2 Inhibitors

MTA-Cooperative PRMT5 Inhibitors

Naphthyridine Derivatives

Crystalline Forms

Multi-Tyrosine Kinase Inhibitor

Substituted Imidazo[1,2-c]pyrimidines

44 patents: Sort by Forward Citations

1. 12747253 - KRas G12D inhibitors (2026-09-29),

2. 12686692 - KRas G12D inhibitors (2026-07-21),

3. 12655160 - KRAS G12D inhibitors (2026-06-16),

4. 12653789 - Adagrasib solid pharmaceutical compositions (2026-06-16),

5. 12630566 - KRas G12D inhibitors (2026-05-19),

6. 12527795 - Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith (2026-01-20),

7. 12485122 - Combination of palbociclib and adagrasib for lung cancer (2025-12-02),

8. 12466838 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof (2025-11-11),

9. 12421253 - Tetrahydropyridopyrimidine pan-KRas inhibitors (2025-09-23),

10. 12421228 - Naphthyridine derivatives as PRC2 inhibitors (2025-09-23),

11. 12398154 - Azaquinazoline pan-KRas inhibitors (2025-08-26),

12. 12383503 - Adagrasib solid pharmaceutical compositions (2025-08-12),

13. 12377101 - Combination therapies (2025-08-05),

14. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

15. 12336995 - Combination therapies (2025-06-24),

Company Overview

Mirati Therapeutics, Inc. is a biotechnology company based in Princeton, NJ, focused on developing innovative therapies for cancer treatment. The company specializes in targeted therapies that address specific genetic and epigenetic drivers of cancer, aiming to improve patient outcomes through precision medicine. Mirati's research encompasses a range of molecular pathways and employs cutting-edge technologies to advance its drug development pipeline, positioning itself as a leader in the oncology space.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

44 Patents

#31 in Princeton, NJ

#332 in New Jersey

#7,956 in US

#15,756 in the World

Princeton, NJ, United States of America

Mirati Therapeutics, Inc.

Forward Citations = 104

65 inventors:

Matthew Arnold Marx (30 out of 30 patents)

James Gail Christensen (23 out of 24 patents)

Aaron Craig Burns (16 out of 20 patents)

4. John Michael Ketcham (16 out of 24 patents)

5. Christopher Ronald Smith (14 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mirati Therapeutics, Inc.. Retrieved from https://idiyas.com/company/mirati-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…